Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Penn Medicine Rittenhouse
mi
from
Philadelphia, PA
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Penn Medicine Rittenhouse
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center Health System
mi
from
Pittsburgh, PA
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center Health System
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Metrolina Neurological Assoc., PA
mi
from
Rock Hill, SC
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Metrolina Neurological Assoc., PA
mi
from
Rock Hill, SC
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Memorial Hermann Hospital
mi
from
Houston, TX
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Memorial Hermann Hospital
mi
from
Houston, TX
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Scott & White Memorial Hospital
mi
from
Temple, TX
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Scott & White Memorial Hospital
mi
from
Temple, TX
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Swedish Neuroscience Institute
mi
from
Seattle, WA
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Swedish Neuroscience Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Center for Neurological Disorders, S.C.
mi
from
Milwaukee, WI
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Center for Neurological Disorders, S.C.
mi
from
Milwaukee, WI
Click here to add this to my saved trials
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated:  12/31/1969
Hôpital Morvan
mi
from
Brest cedex 2,
An Adult Spasticity Registry of OnabotulinumtoxinA Treatment
ASPIRE: Adult SPasticity International REgistry on BOTOX® Treatment
Status: Enrolling
Updated: 12/31/1969
Hôpital Morvan
mi
from
Brest cedex 2,
Click here to add this to my saved trials
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
A Phase II Trial of Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A)Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Chronic Effects of DBS in Parkinson's Disease and Dystonia
Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia
Status: Enrolling
Updated:  12/31/1969
UCSF Surgical Movement Disorders Center
mi
from
San Francisco, CA
Chronic Effects of DBS in Parkinson's Disease and Dystonia
Chronic Effects of Deep Brain Stimulation on Cortical Local Field Potentials in Parkinson's Disease and Dystonia
Status: Enrolling
Updated: 12/31/1969
UCSF Surgical Movement Disorders Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
AMES Treatment of the Proximal Arm in Chronic Stroke
AMES Rehabilitation of the Proximal Arm in Severely Impaired Stroke Patients
Status: Enrolling
Updated:  12/31/1969
Oregon Health and Science University West Campus
mi
from
Beaverton, OR
AMES Treatment of the Proximal Arm in Chronic Stroke
AMES Rehabilitation of the Proximal Arm in Severely Impaired Stroke Patients
Status: Enrolling
Updated: 12/31/1969
Oregon Health and Science University West Campus
mi
from
Beaverton, OR
Click here to add this to my saved trials
Effect of Transcranial Magnetic Stimulation on Recovery of Upper Limb Among Stroke Survivors
Effect of Transcranial Magnetic Stimulation on Motor Recovery of Upper Limb Among Stroke Survivors: Pilot Study
Status: Enrolling
Updated:  12/31/1969
Kessler Foundation
mi
from
West Orange, NJ
Effect of Transcranial Magnetic Stimulation on Recovery of Upper Limb Among Stroke Survivors
Effect of Transcranial Magnetic Stimulation on Motor Recovery of Upper Limb Among Stroke Survivors: Pilot Study
Status: Enrolling
Updated: 12/31/1969
Kessler Foundation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated:  12/31/1969
Lurie Center for Autism, Massachusetts General Hospital
mi
from
Boston, MA
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated: 12/31/1969
Lurie Center for Autism, Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated:  12/31/1969
Center for Autism and the Developing Brain
mi
from
White Plains, NY
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated: 12/31/1969
Center for Autism and the Developing Brain
mi
from
White Plains, NY
Click here to add this to my saved trials
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated:  12/31/1969
Duke Center for Autism and Brain Development
mi
from
Durham, NC
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated: 12/31/1969
Duke Center for Autism and Brain Development
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated:  12/31/1969
Duke University , Genetics Center
mi
from
Durham, NC
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated: 12/31/1969
Duke University , Genetics Center
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated:  12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated: 12/31/1969
Vanderbilt University
mi
from
Nashville, TN
Click here to add this to my saved trials
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated:  12/31/1969
Seattle Children's Hospital Research Institute
mi
from
Seattle, WA
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated: 12/31/1969
Seattle Children's Hospital Research Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated:  12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Phase II Study of Oxytocin in Autism to Improve Reciprocal Social Behaviors
Status: Enrolling
Updated: 12/31/1969
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of Potential Allergenicity of New Soybean Varieties
Evaluation of Potential Allergenicity of New Soybean Varieties
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Evaluation of Potential Allergenicity of New Soybean Varieties
Evaluation of Potential Allergenicity of New Soybean Varieties
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Status: Enrolling
Updated:  12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Status: Enrolling
Updated: 12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Simvastatin for mTBI
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI
Status: Enrolling
Updated:  12/31/1969
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
Simvastatin for mTBI
Simvastatin: Proof-of-Concept for Prevention of Neurodegeneration in Mild TBI
Status: Enrolling
Updated: 12/31/1969
VA Puget Sound Health Care System Seattle Division, Seattle, WA
mi
from
Seattle, WA
Click here to add this to my saved trials
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis
mi
from
Portland, OR
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Jackson, TN
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Jackson, TN
Click here to add this to my saved trials
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
mi
from
Kingsport, TN
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
mi
from
Kingsport, TN
Click here to add this to my saved trials
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Spokane, WA
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Spokane, WA
Click here to add this to my saved trials
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Bruxelles,
Extension in AS: Sustainability of Benefits, Safety and Tolerability
An Extension Study to Evaluate the Sustainability of Clinical Benefits, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Bruxelles,
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Gynecologic Cancer Center
mi
from
Orlando, FL
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Gynecologic Cancer Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
North Shore University
mi
from
Evanston, IL
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
North Shore University
mi
from
Evanston, IL
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Greater Baltimore Medical Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
MD Anderson at Cooper Cancer Center
mi
from
Voorhees, NJ
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
MD Anderson at Cooper Cancer Center
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Women's Cancer Care Associates
mi
from
Albany, NY
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Women's Cancer Care Associates
mi
from
Albany, NY
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Winthrop Gynecologic Oncology Associates
mi
from
Mineola, NY
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Winthrop Gynecologic Oncology Associates
mi
from
Mineola, NY
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Henry-Joyce Cancer Clinic
mi
from
Nashville, TN
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Henry-Joyce Cancer Clinic
mi
from
Nashville, TN
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Aurora St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital for Women
mi
from
Heidelberg,
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital for Women
mi
from
Heidelberg,
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
OSU JamesCare at Mill Run
mi
from
Hilliard, OH
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
OSU JamesCare at Mill Run
mi
from
Hilliard, OH
Click here to add this to my saved trials
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated:  12/31/1969
Palo Alto Foundation Medical Group
mi
from
San Francisco, CA
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Status: Enrolling
Updated: 12/31/1969
Palo Alto Foundation Medical Group
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure
A Randomized, Double-blind, Event-driven, Multicenter Study Comparing the Efficacy and Safety of Rivaroxaban With Placebo for Reducing the Risk of Death, Myocardial Infarction or Stroke in Subjects With Heart Failure and Significant Coronary Artery Disease Following an Episode of Decompensated Heart Failure
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials